BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Pharm Country

  Keytruda Set to Become World’s Top-Selling Drug, Forecast Shows

  While Humira being the top-selling drug is on the decline due to increased competition and expiring patents, Keytruda is set to take the number-one position.

  October 4, 2019

   · 

  3 min read

   · 

  Alex Keown
• 

  Career Advice

  Background Checks for Life Sciences Professionals: What to Expect

  Background checks, especially at the executive level, have become routine in the recruitment process.

  October 4, 2019

   · 

  4 min read

   · 

  Katharine Hansen, PhD
• 

  FDA

  AstraZeneca’s Fasenra Approved for Asthma Using an Auto-Inject Pen

  The approval was based on data from the Phase III GRECO clinical trial and the Phase I AMES trial.

  October 4, 2019

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  FDA Action Alert: PFEnex, Flexion, Alexion and Clearside

  There are several scheduled PDFUA dates for the U.S. Food and Drug Administration over the next two weeks. Here’s a look.

  October 4, 2019

   · 

  4 min read

   · 

  Mark Terry
• 

  Rhode Island to Launch Cell Therapy Training Institute

  This institute will focus on educating and training URI’s nursing and pharmacy students, faculty and staff in immuno-oncology.

  October 4, 2019

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Trump Claims Pharma Industry Is Behind Impeachment Proceedings as Payback

  Trump said that the pharma industry was looking for payback due to his administration’s efforts to lower the costs of prescription drugs.

  October 4, 2019

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Tocagen Cuts 65% of Employees Following Failure of Brain Cancer Treatment

  Less than a month after its Phase III brain cancer treatment failed, San Diego-based Tocagen is undergoing a company restructuring and will reduce its workforce by approximately 65%, the company announced late Thursday.

  October 4, 2019

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Clinical Catch-Up for September 31-October 4

  It was another busy week for clinical trials. Here’s a look.

  October 4, 2019

   · 

  7 min read

   · 

  Mark Terry
• 

  FDA

  Gilead’s Descovy Approved for HIV Prevention

  The only other drug currently approved in the U.S. for HIV PrEP is Gilead’s Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg).

  October 4, 2019

   · 

  3 min read

   · 

  Mark Terry
• 

  Important Advice to Give to Someone Entering the Workforce

  Let’s look at some important things to tell someone who is about to enter the workforce.

  October 4, 2019

   · 

  3 min read

   · 

  Don Potochny